Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21822
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlexiou, G. A.en
dc.contributor.authorFotopoulos, A. D.en
dc.contributor.authorPapadopoulos, A.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorPolyzoidis, K. S.en
dc.contributor.authorTsiouris, S.en
dc.date.accessioned2015-11-24T19:17:52Z-
dc.date.available2015-11-24T19:17:52Z-
dc.identifier.issn0914-7187-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21822-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectBrain/pathology/radionuclide imagingen
dc.subjectBrain Neoplasms/*diagnosis/*pathology/radionuclide imagingen
dc.subjectCell Line, Tumoren
dc.subjectFemaleen
dc.subjectGlioma/diagnosis/*radionuclide imagingen
dc.subjectHumansen
dc.subjectMagnetic Resonance Imaging/methodsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOrganophosphorus Compounds/*pharmacologyen
dc.subjectOrganotechnetium Compounds/*pharmacologyen
dc.subjectPilot Projectsen
dc.subjectRadiopharmaceuticals/*pharmacologyen
dc.subject*Recurrenceen
dc.subjectTomography, Emission-Computed, Single-Photon/*methodsen
dc.subjectTomography, X-Ray Computed/methodsen
dc.titleEvaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s12149-007-0027-x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17634847-
heal.identifier.secondaryhttp://www.springerlink.com/content/qm70606643xq04q1/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractOBJECTIVE: The differentiation between brain tumor recurrence and post-irradiation injury remains an imaging challenge. Computed tomography (CT) and magnetic resonance imaging (MRI) cannot always distinguish between the two. Although glioma cell line studies substantiated a plausible imaging superiority of (99m)Tc-tetrofosmin ((99m)Tc-TF) over other radiopharmaceuticals, little has been reported on its in vivo imaging properties. We assessed (99m)Tc-TF single-photon emission CT (SPECT) in cases where morphologic brain imaging was inconclusive between recurrence and radionecrosis. METHODS: A total of 11 patients (7 men, 4 women) were evaluated. The initial diagnosis was glioblastoma multiforme (4), anaplastic astrocytoma (1), anaplastic oligodendroglioma (3), grade-II astrocytoma (2), and low-grade oligodendroglioma (1). All patients had been operated on and then received adjuvant external-beam radiotherapy. After a mean follow-up period of 25 months, there was clinical suspicion of recurrence, for which (99m)Tc-TF SPECT was performed. RESULTS: In 8/11 cases, an abnormally increased tracer uptake appeared in the region that CT and/or MRI indicated as suspicious; in half of these cases, recurrence was confirmed histologically after surgery and in the other four by growth of the lesion over a 6-month follow-up period, and clinical deterioration. The remaining 3/11 patients had faint tracer uptake in the suspicious region, compatible with radiation injury; these lesions remained morphologically unaltered in a mean 12-month follow-up period, with no clinical deterioration in the patient's condition, a course strongly favoring the diagnosis of radiation injury. CONCLUSIONS: Metabolic brain imaging by (99m)Tc-TF could offer useful information in the workup of treated brain tumors, where radiomorphologic findings between recurrence and radionecrosis are inconclusive.en
heal.journalNameAnn Nucl Meden
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Alexiou-2007-Evaluation of brain.pdf254.61 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons